The vaccine is one of a wave of new drugs heading for the market, including lecanemab, developed by Japanese company Eisai, which received US regulatory approval last year,
Financial Times reported.
In the Takeda deal, AC Immune will receive an upfront payment of $100mn, rising to $2.1bn if milestones are reached, as well as more than 10 per cent in royalties from any worldwide sales.
The Japanese group could advance the product to late-stage, phase 3 trials, AC Immune said, but regulatory approval could take several years.
Early trials had identified no safety concerns, said Andrea Pfeifer, chief executive of the biotech. But AC Immune would not have efficacy data for the drug until it completed a mid-stage trial within the next 12 months.
